JAKUB TOLAR to Iduronidase
This is a "connection" page, showing publications JAKUB TOLAR has written about Iduronidase.
Connection Strength
0.587
-
Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes. Sci Rep. 2019 Oct 01; 9(1):14105.
Score: 0.157
-
Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation. Pediatr Res. 2020 01; 87(1):104-111.
Score: 0.156
-
Synthetic zinc finger nuclease design and rapid assembly. Hum Gene Ther. 2011 Sep; 22(9):1155-65.
Score: 0.089
-
Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of a-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther. 2011 Mar; 19(3):450-60.
Score: 0.085
-
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. J Inherit Metab Dis. 2017 03; 40(2):281-289.
Score: 0.032
-
Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres. Mol Genet Metab. 2016 Mar; 117(3):373-7.
Score: 0.030
-
Lipid composition of whole brain and cerebellum in Hurler syndrome (MPS IH) mice. Neurochem Res. 2011 Sep; 36(9):1669-76.
Score: 0.022
-
A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. Mol Ther. 2005 Sep; 12(3):569-74.
Score: 0.015